Actively Recruiting
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
Led by prof. dr. Rik Schrijvers · Updated on 2025-12-03
20
Participants Needed
1
Research Sites
314 weeks
Total Duration
On this page
Sponsors
P
prof. dr. Rik Schrijvers
Lead Sponsor
R
Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy
CONDITIONS
Official Title
Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with a genetically confirmed or highly suspected disorder causing overactivation of the JAK-STAT pathway
- Healthy individuals without immune-mediated disease eligible as controls
You will not qualify if you...
- Children under 18 years at the time of recruitment
- Individuals unable or unwilling to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Leuven,
Leuven, Vlaams-Brabant, Belgium, 3000
Actively Recruiting
Research Team
R
Rik Schrijvers, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here